Activation of intracellular signaling systems by high-density lipoproteins

Journal of Clinical Lipidology

Volumn 4, Issue 5, 2010, Pages 376-381

  Toth, Peter P ^a,b  

^a Sterling Rock Falls Clinic ^*  (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

G protein coupled receptor; High density lipoproteins; Nitric oxide; Protein kinase; Proteosome; Scavenger receptor BI; Sphingosine phosphate

Indexed keywords

APOLIPOPROTEIN; APOPROTEIN; CELL ADHESION MOLECULE; G PROTEIN COUPLED RECEPTOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; NITRIC OXIDE; PROTEASOME; PROTEIN KINASE; SCAVENGER RECEPTOR BI; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

APOPTOSIS; ATHEROSCLEROSIS; CELL FUNCTION; CELL MIGRATION; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; VASODILATATION;

APOPTOSIS; BLOOD PLATELETS; CELL MOVEMENT; ENDOTHELIAL CELLS; HUMANS; LIPOPROTEINS, HDL; MYOCYTES, SMOOTH MUSCLE; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOLIPIDS;

EID: 77957871747     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.08.011     Document Type: Conference Paper

References (37)

1. T. Vaisar, S. Pennathur, and P.S. Green Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL J Clin Invest 117 2007 746 756
2. J.W. Heinecke The HDL proteome: a marker - and perhaps mediator - of coronary artery disease J Lipid Res 50 Suppl S 2009 167 171
3. B.J. Ansell, M. Navab, and S. Hama Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment Circulation 108 2003 2751 2756
4. M. Navab, G.M. Anantharamaiah, S.T. Reddy, B.J. Van Lenten, B.J. Ansell, and A.M. Fogelman Mechanisms of disease: proatherogenic HDL-an evolving field Nat Clin Prac Endocrinol Metab 2 2006 504 511
5. H.B. Brewer Jr., A.T. Remaley, E.B. Neufeld, F. Basso, and C. Joyce Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease Arterioscler Thromb Vasc Biol 24 2004 1755 1760
6. D.J. Rader Molecular regulation of HDL metabolism and function: implications for novel therapies J Clin Invest 116 2006 3090 3100
7. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
8. M. Aviram, E. Hardak, and J. Vaya Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities Circulation 101 2000 2510 2517
9. Z. Ahmed, A. Ravandi, and G.F. Maguire Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor J Biol Chem 276 2001 24473 24481
10. J.A. Leopold, and J. Loscalzo Oxidative enzymopathies and vascular disease Arterioscler Thromb Vasc Biol 25 2005 1332 1340
11. L. Calabresi, G. Franceschini, and C.R. Sirtori Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins Biochem Biophys Res Commun 238 1997 61 65
12. G. Assmann, and J.R. Nofer Atheroprotective effects of high-density lipoproteins Ann Rev Med 54 2003 321 341
13. B.G. Drew, N.H. Fidge, G. Gallon-Beaumier, B.E. Kemp, and B.A. Kingwell High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation Proc Natl Acad Sci U S A 101 2004 6999 7004
14. G.W. Cockerill, J. Saklatvala, and S.H. Ridley High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2 Arterioscler Thromb Vasc Biol 19 1999 910 917
15. M. Tolle, A. Pawlak, and M. Schuchardt HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production Arterioscler Thromb Vasc Biol 28 2008 1542 1548
16. L. Calabresi, M. Gomaraschi, and G. Franceschini Endothelial protection by high-density lipoproteins: from bench to bedside Arterioscler Thromb Vasc Biol 23 2003 1724 1731
17. J. Beitz, and H.J. Mest Thromboxane A2 (TXA2) formation by washed human platelets under the influence of low and high density lipoproteins from healthy donors Prostaglandins Leukot Med 23 1986 303 309
18. J.H. Griffin, K. Kojima, C.L. Banka, L.K. Curtiss, and J.A. Fernandez High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C J Clin Invest 103 1999 219 227
19. J.R. Nofer, M. Walter, and B. Kehrel HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate Arterioscler Thromb Vasc Biol 18 1998 861 869
20. Y. Yatomi, F. Ruan, S. Hakomori, and Y. Igarashi Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets Blood 86 1995 193 202
21. P. Hanel, P. Andreani, and M.H. Graler Erythrocytes store and release sphingosine 1-phosphate in blood FASEB J 21 2007 1202 1209
22. K.M. Argraves, and W.S. Argraves HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects J Lipid Res 48 2007 2325 2333
23. F. Okajima Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim Biophys Acta 1582 2002 132 137
24. J.R. Nofer, M. van der Giet, and M. Tolle HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3 J Clin Invest 113 2004 569 581
25. M. Krieger Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI Annu Rev Biochem 68 1999 523 558
26. M. Krieger Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems J Clin Invest 108 2001 793 797
27. C. Mineo, I.S. Yuhanna, M.J. Quon, and P.W. Shaul High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases J Biol Chem 278 2003 9142 9149
28. C. Mineo, and P.W. Shaul HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action Trends Cardiovasc Med 13 2003 226 231
29. T. Sanchez, and T. Hla Structural and functional characteristics of S1P receptors J Cell Biochem 92 2004 913 922
30. J.R. Nofer, and G. Assmann Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids Trends Cardiovasc Med 15 2005 265 271
31. P. Libby Current concepts of the pathogenesis of the acute coronary syndromes Circulation 104 2001 365 372
32. H. Bujo, and Y. Saito Modulation of smooth muscle cell migration by members of the low-density lipoprotein receptor family Arterioscler Thromb Vasc Biol 26 2006 1246 1252
33. P. Libby, and M. Aikawa Mechanisms of plaque stabilization with statins Am J Cardiol 91 2003 4B 8B
34. R. Noor, U. Shuaib, and C.X. Wang High-density lipoprotein cholesterol regulates endothelial progenitor cells by increasing eNOS and preventing apoptosis Atherosclerosis 192 2007 92 99
35. J.R. Nofer, B. Kehrel, M. Fobker, B. Levkau, G. Assmann, and A. von Eckardstein HDL and arteriosclerosis: beyond reverse cholesterol transport Atherosclerosis 161 2002 1 16
36. P. Libby, and M. Aikawa Evolution and stabilization of vulnerable atherosclerotic plaques Jpn Circ J 65 2001 473 479
37. J.R. Nofer, M.F. Brodde, and B.E. Kehrel High-density lipoproteins, platelets and the pathogenesis of atherosclerosis Clin Exp Pharmacol Physiol 37 2010 726 735